Biotech companies at AAPS 2026 PharmSci 360
Oct 25–28, 2026 New Orleans, LA ~4k attendees Website
32 biotech companies are at AAPS 2026 PharmSci 360 — 39 presentations on the program. Most represented: Beam Therapeutics (4 on the program), Humanitas Global Health (4 on the program), Ionis Pharmaceuticals (3 on the program). 30 of them have their own page in this guide. As of Oct 20, 2026.
Topic
Top represented
Showing 1–17 of 32 organizations
| Organization | AAPS 2026 PharmSci 360 Attendance |
|---|---|
Beam Therapeutics Cambridge, MA | |
Biotechnology company developing base-editing medicines that make precise single-letter changes to genes. | Talk Mon Oct 26 1:30pm–2:30pm Session Tue Oct 27 9:00am–11:00am Symposium: Measuring the Unmeasurable: Bioanalytical Innovation for Emerging Modalities Talk Tue Oct 27 1:30pm–2:30pm Talk Tue Oct 27 1:30pm–2:30pm |
Develops therapeutics and AI-driven health platforms, including a prescription medication safety program. | |
Ionis Pharmaceuticals Carlsbad, CA | |
Develops RNA-targeted medicines, chiefly antisense oligonucleotides. | Poster Mon Oct 26 12:30pm–1:30pm Same Protein, Different siRNA: Hybridization-Driven Plasma Matrix Interference in an Intact hECL Assay Is Reversed by Hybridization Buffer and LNA Capture-Probe Optimization Poster Mon Oct 26 1:30pm–2:30pm Challenges in Analyzing GFAP in a Clinical Trial in Individuals with Alexander Disease Poster Wed Oct 28 9:30am–10:30am Phase 1 Evaluation of the Effect of Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Olezarsen |
Japanese chemical maker whose healthcare business develops transdermal patch drug products through its KM Transderm subsidiary. | Poster Tue Oct 27 10:30am–11:30am In Vivo Antiemetic Activity of Pulsed Iontophoretic Transdermal Delivery of Palonosetron in a Ferret Emesis Model Poster Wed Oct 28 9:30am–10:30am Development of a Blonanserin Transdermal Patch with Reduced Patch Size and Skin Irritation for Improved Patient Convenience |
Heart health company developing treatments for cardiovascular diseases such as genetic dilated cardiomyopathy and aortic valve stenosis. | Session Tue Oct 27 3:00pm–4:00pm Rapid Fire: Nitrosamine Risk Assessment & Advanced Analytical Characterization Session Wed Oct 28 3:00pm–4:00pm Rapid Fire: Advanced Modalities, Biologics & Next-Generation Characterization |
Moderna Cambridge, MA | |
Biotech developing and marketing mRNA medicines and vaccines, including COVID-19 and RSV vaccines. | Talk Mon Oct 26 9:30am–10:00am Talk Mon Oct 26 3:45pm–4:00pm |
Genomic medicine company using zinc finger technology to develop treatments for neurological and rare genetic diseases. | Session Tue Oct 27 9:00am–11:00am Symposium: Advanced Structural and Biophysical Characterization of Lipid Nanoparticle Systems and Biosimilars Session Wed Oct 28 9:00am–11:00am Symposium: Digital Transformation Through Mechanistic Modeling, QbD, and Collaborative Innovation |
Denali Therapeutics South San Francisco, CA | |
Biotech developing therapies for neurodegenerative diseases, engineered to cross the blood-brain barrier. | Talk Mon Oct 26 10:30am–11:30am |
Halozyme San Diego, CA | |
Biotech whose ENHANZE enzyme technology lets partners' biologics be given by subcutaneous injection; also makes auto-injector devices. | Talk Wed Oct 28 2:30pm–3:30pm |
Develops precision therapies for gastrointestinal disorders, including inflammatory bowel disease and infectious diarrhea. | Session Wed Oct 28 9:00am–11:00am Symposium: AI-Enabled Predictive Manufacturing and Product Intelligence |
Neurocrine Biosciences San Diego, CA | |
Neuroscience-focused biopharmaceutical company developing and marketing treatments for neurological, neuroendocrine and neuropsychiatric disorders. | Session Mon Oct 26 3:00pm–4:00pm Rapid Fire: Bioassay and Immunogenicity Decision Tools |
Q QuadMedicine Seongnam, South Korea | |
Korean developer of microneedle array patches for transdermal delivery of drugs and vaccines. | Talk Mon Oct 26 3:15pm–3:30pm |
Arcus Biosciences Hayward, CA | |
Clinical-stage drug developer working on small-molecule and antibody therapies, mainly for cancer. | Poster Mon Oct 26 9:30am–10:30am Selection of Excipients for Direct Compression Process: A Comprehensive Evaluation of Compression Properties and Statistical Modeling |
Immunology company developing antibody medicines for severe autoimmune diseases. | Poster Mon Oct 26 9:30am–10:30am Evaluation of Diagnostic and Pharmacodynamic Values of a Particle-Based Multianalyte Assay to Measure Myositis-Specific Autoantibodies |
Biograil Roskilde, Denmark | |
Preclinical company developing an oral capsule platform to deliver injectable biologic drugs by mouth. | Poster Tue Oct 27 11:30am–12:30pm The BIONDD® Capsule Delivers Oral Semaglutide with Bioavailability Comparable to Subcutaneous Wegovy® in Awake Dogs |
B BrYet Houston, TX | |
Drug developer using nanoporous silicon microparticles to deliver cancer therapies to tumors, chiefly in metastatic liver and lung disease. | Poster Tue Oct 27 3:30pm–4:30pm Advancing Antibody Delivery with the Injectable Si-Plateloid TM Nanoporous Silicon Platform |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse AAPS 2026 PharmSci 360 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Association of Pharmaceutical Scientists (AAPS). Submit a correction